Paradigm Shift

In Cancer Treatment

Learn More

Salarius is a cancer-focused biotechnology company developing treatments for patients who need them the most.

Our technologies correct the dysregulated gene expression of diseased cells and thereby inhibit cancer progression. In certain cancers, the proteins that regulate gene expression become dysregulated and incorrectly turn genes “on” or “off,” which can lead to disease development and progression. We are developing two classes of drugs that address gene dysregulation: epigenetic drugs and targeted protein degraders. Our technologies have the potential to work in both liquid and solid tumors. We are currently in Phase 1/2 trials with our epigenetic drug, SP-2577, and in IND-enabling studies with SP-3164, a targeted protein degrader. Our hope is to advance these drugs so that they can positively influence cancer patients’ lives.

Salarius is the recipient of a 3-year $16.1 million Cancer Prevention and Research Institute of Texas (CPRIT) New Company Product Development award, is located in the Jlabs@TMC facility in Houston, Texas.

News & Events